UPC vs. RNAZ, SRNE, TFFP, HEPA, HSTO, SMFL, SCPS, VAXX, NAVB, and EVLO
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include TransCode Therapeutics (RNAZ), Sorrento Therapeutics (SRNE), TFF Pharmaceuticals (TFFP), Hepion Pharmaceuticals (HEPA), Histogen (HSTO), Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.
Universe Pharmaceuticals vs.
Universe Pharmaceuticals (NYSE:UPC) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
In the previous week, TransCode Therapeutics had 9 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 9 mentions for TransCode Therapeutics and 0 mentions for Universe Pharmaceuticals. TransCode Therapeutics' average media sentiment score of 0.36 beat Universe Pharmaceuticals' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media.
Universe Pharmaceuticals' return on equity of 0.00% beat TransCode Therapeutics' return on equity.
TransCode Therapeutics has a consensus target price of $20.00, indicating a potential upside of 3,981.63%. Given TransCode Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Universe Pharmaceuticals.
Universe Pharmaceuticals has higher revenue and earnings than TransCode Therapeutics.
Universe Pharmaceuticals has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
TransCode Therapeutics received 15 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Universe Pharmaceuticals beats TransCode Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:UPC) was last updated on 3/30/2025 by MarketBeat.com Staff
Buy UPC Stock Free UPC Stock Alerts